Tags

Type your tag names separated by a space and hit enter

Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives.
Isr Med Assoc J. 2020 04; 22(4):203-210.IM

Authors+Show Affiliations

Immunology and Allergy Laboratory Unit, San Giovanni di Dio Hospital, Florence, Italy.Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.Reumatology Unit, S. Giovanni di Dio Hospital, Florence, Italy.Immunology and Allergy Laboratory Unit, San Giovanni di Dio Hospital, Florence, Italy.Immunology and Allergy Laboratory Unit, San Giovanni di Dio Hospital, Florence, Italy.Allergy and Clinical Immunology, San Giovanni di Dio Hospital, Florence, Italy.Laboratory of Clinical Pathology and Immunoallergy, Florence-Prato, Italy.Laboratory of Clinical Pathology, San Giovanni di Dio Hospital, Florence, Italy.Immunology and Allergy Unit, San Maria degli Angeli Hospital, Pordenone, Italy.Laboratory of Clinical Pathology, San Antonio Hospital, Tolmezzo, Italy.SIPMeL, Castelfranco Veneto, Veneto, Italy.Institute of Clinical Pathology, University of Udine, Udine, Italy.Clinic of Rheumatology, ASUFC, Department of Medicine (DAME), University of Udine, Udine, Italy.Reumatology Unit, S. Giovanni di Dio Hospital, Florence, Italy.Immunology and Allergy Laboratory Unit, San Giovanni di Dio Hospital, Florence, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32286019

Citation

Infantino, Maria, et al. "Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives." The Israel Medical Association Journal : IMAJ, vol. 22, no. 4, 2020, pp. 203-210.
Infantino M, Damiani A, Gobbi FL, et al. Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. Isr Med Assoc J. 2020;22(4):203-210.
Infantino, M., Damiani, A., Gobbi, F. L., Grossi, V., Lari, B., Macchia, D., Casprini, P., Veneziani, F., Villalta, D., Bizzaro, N., Cappelletti, P., Fabris, M., Quartuccio, L., Benucci, M., & Manfredi, M. (2020). Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. The Israel Medical Association Journal : IMAJ, 22(4), 203-210.
Infantino M, et al. Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. Isr Med Assoc J. 2020;22(4):203-210. PubMed PMID: 32286019.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. AU - Infantino,Maria, AU - Damiani,Arianna, AU - Gobbi,Francesca Li, AU - Grossi,Valentina, AU - Lari,Barbara, AU - Macchia,Donatella, AU - Casprini,Patrizia, AU - Veneziani,Francesca, AU - Villalta,Danilo, AU - Bizzaro,Nicola, AU - Cappelletti,Piero, AU - Fabris,Martina, AU - Quartuccio,Luca, AU - Benucci,Maurizio, AU - Manfredi,Mariangela, PY - 2020/4/15/entrez PY - 2020/4/15/pubmed PY - 2020/4/18/medline SP - 203 EP - 210 JF - The Israel Medical Association journal : IMAJ JO - Isr Med Assoc J VL - 22 IS - 4 SN - 1565-1088 UR - https://www.unboundmedicine.com/medline/citation/32286019/Serological_Assays_for_SARS_CoV_2_Infectious_Disease:_Benefits_Limitations_and_Perspectives_ L2 - http://www.ima.org.il/IMAJ/ViewArticle.aspx?year=2020&month=04&page=203 DB - PRIME DP - Unbound Medicine ER -